Drugs / Iron Carboxymaltose
Iron Carboxymaltose
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03957057 | Sep 2020 → Apr 2022 | deficiency anemia, iron deficiency anemia | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT06350955 | May 2024 → Jun 2026 overdue | hypophosphatemia | Lucie Favre | Recruiting | No outcome recorded |
| Phase 4 | NCT03305705 | Oct 2017 → Aug 2019 | disorder of iron metabolism and transport | Albina Nowak, MD | Unknown | No outcome recorded |
| Phase 4 | NCT03042130 | Dec 2016 → Feb 2018 | congestive heart failure | Tel-Aviv Sourasky Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01374776 | Feb 2013 → Sep 2014 | L-ferritin deficiency | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT01519830 | Jan 2012 → Jan 2013 | — | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04475887 Comparator | Jul 2020 → Dec 2022 | — | Medical University of Vienna | Unknown | No outcome recorded |
Press releases naming this drug 8 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iron Carboxymaltose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06350955 ↗ |
| Known as | Ferinject | “Intravenous Iron-induced Hypophosphatemia in Patients With Roux-en-Y Gastric Bypass: a Single-blind, Randomized Clinical Trial Comparing Iron Isomaltoside (Monofer®) and Ferric...” NCT06350955 ↗2“15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously” NCT01374776 ↗ “Iron carboxymaltose (Ferinject)” NCT01519830 ↗ |
| Known as | ferric carboxymaltose | “single dose of 500 mg ferric carboxymaltose” NCT06350955 ↗1“ferric carboxymaltose (Iroprem®)” NCT03957057 ↗ |
| Known as | Iroprem | “ferric carboxymaltose (Iroprem®)” NCT03957057 ↗ |
| Route | Intravenous | “Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously” NCT01374776 ↗ |